The development of microorganisms with improved antibiotic production is an important goal in the commercialization of new Pharmaceuticals or in lowering the cost of established drugs. We report a way to achieve this for biosynthetic intermediates of an antibiotic made by the polyketide pathway whose earliest steps involve a Type II multienzyme complex. Introduction of the tcmKLM β-ketoacyl: ACP synthase and acyl carrier protein (ACP) genes or just the tcmM ACP gene into the tetracenomycin (Tcm) C-producing Streptomyces glaucescens wild-type strain, or its tcmN or tcmO blocked mutants, on high copy vectors under the control of strong promoters caused a 2 to 30-fold overproduction of Tcm D3 and some other biosynthetic intermediates (or shunt products) and a 25 to 30% increase in Tcm C production relative to the control strains carrying the plasmid vector only. However, Tcm C production was not greater than that obtained with the vector-free wild-type strain. The unexpected effect of increased ACP on Tcm D3 production suggests that the level of this protein can influence either the activity or level of the three other components of the Tcm polyketide synthase.
提高抗生素生产能力的微
生物开发是新型药物商业化或降低现有药物成本的重要目标。我们报告了一种通过
多肽途径生产抗生素
生物合成中间体的途径,该途径的早期步骤涉及II型多酶复合物。将tcmKLM β-酮酰基:ACP合成酶和酰基载体蛋白(ACP)
基因或仅将tcmM ACP
基因引入
四环素(Tcm)C生产链霉菌野生型菌株或其tcmN或tcmO阻断突变体,在高拷贝载体上,在强启动子的控制下,与仅携带
质粒载体的对照菌株相比,Tcm D3和其他一些
生物合成中间体(或分流产物)的产量提高了2至30倍,Tcm C的产量提高了25%至30%。然而,Tcm C的产量并不比无载体野生型菌株的产量高。ACP对Tcm D3产量增加的意外影响表明,这种蛋白质的
水平会影响Tcm多�